{
    "clinical_study": {
        "@rank": "109183", 
        "arm_group": [
            {
                "arm_group_label": "ESBA1008", 
                "arm_group_type": "Experimental", 
                "description": "ESBA1008 solution, 7 intravitreal (IVT) injections, as specified in protocol"
            }, 
            {
                "arm_group_label": "EYLEA", 
                "arm_group_type": "Active Comparator", 
                "description": "Aflibercept, 8 intravitreal (IVT) injections, as specified in protocol"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy and safety of ESBA1008 versus EYLEA\u00ae in\n      the treatment of exudative age-related macular degeneration."
        }, 
        "brief_title": "Efficacy and Safety Study of ESBA1008 Versus EYLEA\u00ae", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Exudative Age-Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Wet Macular Degeneration"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Give written informed consent; be able to make the required study visits and follow\n             instructions.\n\n          -  Diagnosis of wet age-related macular degeneration, as specified in protocol.\n\n          -  Best-corrected visual acuity (BCVA) as specified in protocol\n\n          -  Other protocol-specified inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Either eye: Any active ocular or periocular infection or active intraocular\n             inflammation.\n\n          -  Study eye: Any approved or investigational treatment for exudative AMD other than\n             vitamin supplements.\n\n          -  Study eye: Any current or history of macular or retinal disease other than exudative\n             AMD.\n\n          -  Study eye: Any concurrent intraocular condition that, in the opinion of the\n             Investigator, could require medical or surgical intervention during the course of the\n             study to prevent or treat vision loss, or that limits the potential to gain visual\n             acuity with the investigational product.\n\n          -  Study eye: Uncontrolled glaucoma.\n\n          -  Study eye: Any ocular disease that, in the opinion of the Investigator, could\n             compromise the visual acuity.\n\n          -  Study eye: History of eye surgery, as specified in protocol.\n\n          -  Study eye: Use of corticosteroids, as specified in protocol.\n\n          -  Any medical condition that, in the opinion of the Investigator, would preclude\n             scheduled study visits, completion of the study or safe administration of\n             investigational product.\n\n          -  Any screening laboratory result that, in the opinion of the Investigator, would make\n             the patient unsuitable for study participation.\n\n          -  History of hypersensitivity to any component used in the study, as assessed by the\n             Investigator.\n\n          -  Women of childbearing potential: Lactating, pregnant, plan to become pregnant, or not\n             using adequate birth control, as specified in protocol.\n\n          -  Participation in an investigational drug or device study within time period specified\n             in protocol.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "173", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796964", 
            "org_study_id": "C-12-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "ESBA1008", 
                "description": "For intravitreal (IVT) injection", 
                "intervention_name": "ESBA1008 solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EYLEA", 
                "description": "For intravitreal (IVT) injection", 
                "intervention_name": "Aflibercept", 
                "intervention_type": "Drug", 
                "other_name": "EYLEA\u00ae"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Age-Related Macular Degeneration", 
            "Wet", 
            "Exudative", 
            "AMD", 
            "Intravitreal injection", 
            "Retina"
        ], 
        "lastchanged_date": "November 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center at 1-888-451-3937 for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA\u00ae in Subjects With Exudative Age-Related Macular Degeneration", 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Siobhan Garbutt, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "As measured by Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) testing", 
            "measure": "Change from Baseline in Visual Acuity at Week 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796964"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "As measured by Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) testing", 
                "measure": "Change from Baseline in Visual Acuity at Week 16", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "description": "As measured by Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) testing", 
                "measure": "Change from Baseline in Visual Acuity, Up to Week 56", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Up to Week 56"
            }, 
            {
                "description": "As measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)", 
                "measure": "Change from Baseline in Central Subfield (CSF) Thickness by Visit", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 56"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}